Immunotherapy and radiation combo shows promise against rare sarcomas
NCT ID NCT03474094
First seen Feb 02, 2026 · Last updated May 24, 2026 · Updated 15 times
Summary
This study tests whether adding the immunotherapy drug atezolizumab to standard radiation therapy can shrink soft tissue sarcomas more effectively before surgery. About 62 adults with operable sarcoma will receive different sequences of radiation, atezolizumab, and surgery. The goal is to see if the combination increases tumor cell death (necrosis) compared to radiation alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA,SOFT TISSUE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Centre Léon Bérard
Lyon, 69008, France
-
Centre Oscar Lambret
Lille, France
-
Institut Bergonie
Bordeaux, France
-
Institut Claudius Regaud
Toulouse, 31059, France
-
Institut Gustave Roussy
Villejuif, 94805, France
-
Royal Marsden Hospital
London, United Kingdom
Conditions
Explore the condition pages connected to this study.